| Synonym |
| Thai / English name |
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12 (M/F=6/6)N(Treatment) : 12 (M/F=6/6)Sex : Both sexAge : 67+/-5.2 yrs.Route : Oral administrationDose/Conc.(herb) : 60 mg four times daily (standardized to 24% flavones glycoside and 6% terpene lactones)Duration : 28 daysType of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : 8 mgResult : NegativeRemark :Note : Twelve healthy volunteers were randomly assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe drug cocktails of midazolam, caffeine, chlorzoxazone and debrisoquine were administered before (days -1, 0) and at the end of supplementation (days 27, 28). Pre- and post-supplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour), paraxanthine/caffeine serum ratios (6-hour), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour) and debrisoquine urinary recovery ratios (8-hour), respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12 (M/F=6/6)N(Treatment) : 12 (M/F=6/6)Sex : Both sexAge : 67+/-5.2 yrs.Route : Oral administrationDose/Conc.(herb) : 60 mg four times daily (standardized to 24% flavones glycoside and 6% terpene lactones)Duration : 28 daysType of interaction : PharmacokineticsInteraction with drug : CaffeineDose/Conc.(drug) : 100 mgResult : PositiveRemark :Note : Twelve healthy volunteers were randomly assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe drug cocktails of midazolam, caffeine, chlorzoxazone and debrisoquine were administered before (days -1, 0) and at the end of supplementation (days 27, 28). Pre- and post-supplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour), paraxanthine/caffeine serum ratios (6-hour), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour) and debrisoquine urinary recovery ratios (8-hour), respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12 (M/F=6/6)N(Treatment) : 12 (M/F=6/6)Sex : Both sexAge : 67+/-5.2 yrs.Route : Oral administrationDose/Conc.(herb) : 60 mg four times daily (standardized to 24% flavones glycoside and 6% terpene lactones)Duration : 28 daysType of interaction : PharmacokineticsInteraction with drug : ChlorzoxazoneDose/Conc.(drug) : 500 mgResult : NegativeRemark : Long-term administration of G. biloba had no modulatary effect on CYP2E1.Note : Twelve healthy volunteers were randomly assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe drug cocktails of midazolam, caffeine, chlorzoxazone and debrisoquine were administered before (days -1, 0) and at the end of supplementation (days 27, 28). Pre- and post-supplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour), paraxanthine/caffeine serum ratios (6-hour), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour) and debrisoquine urinary recovery ratios (8-hour), respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12 (M/F=6/6)N(Treatment) : 12 (M/F=6/6)Sex : Both sexAge : 67+/-5.2 yrs.Route : Oral administrationDose/Conc.(herb) : 60 mg four times daily (standardized to 24% flavones glycoside and 6% terpene lactones)Duration : 28 daysType of interaction : PharmacokineticsInteraction with drug : Debrisoquin*/Debrisoquine/Debrisochinum/IsocaramidineDose/Conc.(drug) : 5 mgResult : PositiveRemark :Note : Twelve healthy volunteers were randomly assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe drug cocktails of midazolam, caffeine, chlorzoxazone and debrisoquine were administered before (days -1, 0) and at the end of supplementation (days 27, 28). Pre- and post-supplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour), paraxanthine/caffeine serum ratios (6-hour), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour) and debrisoquine urinary recovery ratios (8-hour), respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : EGb761Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 50 (M/F=50/-)N(Treatment) : 50 (M/F=50/-)Sex : MaleAge : 20-44 yrs. (mean 27.2+/-4.9)Route : Oral administrationDose/Conc.(herb) : EGb 761 120 mg of dry extract twice dailyDuration : 7 daysType of interaction : PharmacokineticsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : 500 mg dailyResult : PositiveRemark : Results: Acetylsalicylic acid (ASA) and the combination of ASA + EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of measns: 1.01, 90% Cl 0.86, 1.19) and agonist-induced platelet aggregation (collagen-induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00 , 90% Cl 0.95, 1.05; adenosine diphosphate-induced platelet aggregation - ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06). Both treatments were well tolerated , and both the number and nature of adverse events in the two groups were similar.Note : 50 healthy male subjects were randomly allocated in equal numbers to one of two possible treatment sequences, i.e. ASA followed by ASA + EGb 761 or ASA + EGb 761 followed by ASA. Each treatment lasted 7 days; the washout period between treatments was 3 weeks. Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo-coated tablet in the morning and placebo tablet + placebo-coated tablet in the evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg-coated tablet in the morning and placebo tablet + EGb 761 120 mg-coated tablet in the evening) resulting in a daily dose of ASA 500 mg in the ASA group and 500 mg ASA + 240 mg EGb 761 in the ASA + EGb 761 group.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : EGb761Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 50 (M/F=50/-)N(Treatment) : 50 (M/F=50/-)Sex : MaleAge : 20-44 yrs. (mean 27.2+/-4.9)Route : Oral administrationDose/Conc.(herb) : EGb 761 120 mg of dry extract twice dailyDuration : 7 daysType of interaction : PharmacokineticsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : 500 mg dailyResult : PositiveRemark : Results: Acetylsalicylic acid (ASA) and the combination of ASA + EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of measns: 1.01, 90% Cl 0.86, 1.19) and agonist-induced platelet aggregation (collagen-induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00 , 90% Cl 0.95, 1.05; adenosine diphosphate-induced platelet aggregation - ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06). Both treatments were well tolerated , and both the number and nature of adverse events in the two groups were similar.Note : 50 healthy male subjects were randomly allocated in equal numbers to one of two possible treatment sequences, i.e. ASA followed by ASA + EGb 761 or ASA + EGb 761 followed by ASA. Each treatment lasted 7 days; the washout period between treatments was 3 weeks. Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo-coated tablet in the morning and placebo tablet + placebo-coated tablet in the evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg-coated tablet in the morning and placebo tablet + EGb 761 120 mg-coated tablet in the evening) resulting in a daily dose of ASA 500 mg in the ASA group and 500 mg ASA + 240 mg EGb 761 in the ASA + EGb 761 group.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : The standardized Ginkgo biloba leaf extract (EGb 761)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : EGb 761 100 mcg/mlDuration : Transfected cells were then treated with EGb 761 for 24 h.Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Result: EGb 761 and its flavonoids, especially Que and Kae, increased the activity of human constitutive androstane receptor (hCAR) to an extent that exceeds that of CITCO (CAR agonist) treatment in transfected HepG2 cells.Note : Abbreviations: AhR = Arylhydrocarbon receptor GA = Ginkgolide A, GB = Ginkgolide B, CAR = Constitutive androstane receptor, BB = Bilobalide, Que = Quercetin, Kae = Kaempferol, Tam = Tamarexetin
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : quercetin (Que)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Que 25 mcg/mlDuration : Transfected cells were then treated with Que for 24 h.Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Result: EGb 761 and its flavonoids, especially Que and Kae, increased the activity of human constitutive androstane receptor (hCAR) to an extent that exceeds that of CITCO (CAR agonist) treatment in transfected HepG2 cells.Note : Abbreviations: AhR = Arylhydrocarbon receptor GA = Ginkgolide A, GB = Ginkgolide B, CAR = Constitutive androstane receptor, BB = Bilobalide, Que = Quercetin, Kae = Kaempferol, Tam = Tamarexetin
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Kaempferol (Kae)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Kae 20 mcg/mlDuration : Transfected cells were then treated with Kae for 24 h.Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Result: EGb 761 and its flavonoids, especially Que and Kae, increased the activity of human constitutive androstane receptor (hCAR) to an extent that exceeds that of CITCO (CAR agonist) treatment in transfected HepG2 cells.Note : Abbreviations: AhR = Arylhydrocarbon receptor GA = Ginkgolide A, GB = Ginkgolide B, CAR = Constitutive androstane receptor, BB = Bilobalide, Que = Quercetin, Kae = Kaempferol, Tam = Tamarexetin
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : tamarixetin (Tam)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Tam 10 mcg/mlDuration : Transfected cells were then treated with Tam for 24 h.Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Result: EGb 761 and its flavonoids, especially Que and Kae, increased the activity of human constitutive androstane receptor (hCAR) to an extent that exceeds that of CITCO (CAR agonist) treatment in transfected HepG2 cells.Note : Abbreviations: AhR = Arylhydrocarbon receptor GA = Ginkgolide A, GB = Ginkgolide B, CAR = Constitutive androstane receptor, BB = Bilobalide, Que = Quercetin, Kae = Kaempferol, Tam = Tamarexetin
